We share the market value of

0B
in 2022
0%
CAGR from 2022– 2030

LizAI’s Services

Our goal is to provide services to insurance companies, hospitals, pharmaceutical companies, and directly to users.

Determining the Best-Fit Treatment

LizAI platform helps doctors determine the best-fit approved treatment.

Supporting Drug Development

LizAI platform supports new drug development by using big database to screen multiple drug targets.

Predicting Clinical Outcomes

LizAI platform predicts the best treatment’s clinical outcomes based on the patient’s clinical information.

Accelerating Clinical Studies

LizAI platform helps define lead drugs, design clinical studies, thus accelerating the process and saving cost.

The significant burdens posed by Obese Diabetes (type II)

0B
in 2022
0%
US Population

LizAI first-Line Product

Provides solutions to the challenges in treating Obese Diabetes (type II), in which area LizAI Inc. is the pioneer.

40%

US population

Lives with a high risk of Obese Diabetes, posing a significant burden on the healthcare system. The total yearly cost for these patients is $327B in the US.

There are at least 60 approved medicines. Moreover, obese diabetes itself is multifactorial and complex, which in many cases leads to other health complications (e.g., cardiac diseases, stroke, liver and kidney diseases, cancers, etc.) and requires combined drugs treatment. This is thus significantly challenging for doctors to evaluate the patients’ condition and effectively provide multiple drugs prescription.

Additionally, according to clinical reports, many of the prescribed drugs do not work as expected and need to be re-defined for each patient’s needs. The drug-to-drug interaction has not been systematically recorded and deeply studied, posing high risks of disease complications. Precision treatment is thus urgently needed.